Fulcrum Therapeutics

$13.95
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$2.22 (+18.93%) Today

$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell FULC and other stocks, options, and ETFs commission-free!

About FULC

Fulcrum Therapeutics, Inc. Common Stock, also called Fulcrum Therapeutics, is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA. The listed name for FULC is Fulcrum Therapeutics, Inc. Common Stock.

CEO

Robert J. Gould

Employees

Headquarters

Cambridge, Massachusetts

Founded

2015

Market Cap

383.10M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

97.36K

High Today

$13.98

Low Today

$11.67

Open Price

$12.00

Volume

1.48M

52 Week High

$22.39

52 Week Low

$7.01

Collections

FULC Earnings

-$9.21

-$6.14

-$3.07

$0.00

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Mar 4, Pre-Market